Curis, Inc.  

(Public, NASDAQ:CRIS)   Watch this stock  
Find more results for CRIS
1.43
+0.07 (5.15%)
Nov 25 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.34 - 1.47
52 week 1.19 - 3.65
Open 1.39
Vol / Avg. 641,205.00/296,192.00
Mkt cap 116.15M
P/E     -
Div/yield     -
EPS -0.20
Shares 86.00M
Beta 2.22
Inst. own 42%
Feb 18, 2015
Q4 2014 Curis Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Nov 24, 2014
Curis Inc at Brean Capital's Life Sciences Summit Conference
Nov 19, 2014
Curis Inc at Stifel Healthcare Conference
Nov 10, 2014
Q3 2014 Curis Inc Earnings Release
Nov 10, 2014
Q3 2014 Curis Inc Earnings Call
Oct 7, 2014
Curis Inc at BIO Investor Forum
Sep 10, 2014
Curis Inc at Rodman & Renshaw Global Investment Conference
Sep 3, 2014
Curis Inc at Robert W. Baird & Co. Inc Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -316.18% -82.14%
Operating margin -269.32% -62.77%
EBITD margin - -61.82%
Return on average assets -31.50% -16.39%
Return on average equity -60.44% -31.02%
Employees 33 -
CDP Score - -

Address

4 Maguire Road
LEXINGTON, MA 02421
United States - Map
+1-617-5036500 (Phone)
+1-617-5036501 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Curis, Inc. is a drug discovery and development company that is committed to leveraging signaling pathway drug technologies in seeking to develop next generation network-targeted cancer therapies. The Company conducts its research and development programs both internally and through strategic collaborations. Its advanced program is Hedgehog pathway inhibitor program under collaboration with Genentech, Inc., a wholly owned member of the Roche Group. The lead drug candidate being developed under this program is Erivedge, a orally-administered small molecule Hedgehog pathway inhibitor, which is also known as vismodegib, GDC-0449 and RG3616. In October 2011, the Company completed a Phase Ib expansion trial to test CUDC-101. The Company�s other development candidate under collaboration is Debio 0932 (formerly CUDC-305).

Officers and directors

James R. McNab Jr. Independent Chairman of the Board
Age: 70
Bio & Compensation  - Reuters
Ali Fattaey Ph.D. President, Chief Executive Officer, Director
Age: 49
Bio & Compensation  - Reuters
Daniel R. Passeri J.D. Vice Chairman of the Board
Age: 53
Bio & Compensation  - Reuters
Michael P. Gray Chief Financial Officer
Age: 43
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Jaye Viner M.D. Chief Medical Officer, Executive Vice President
Age: 57
Bio & Compensation  - Reuters
Mani Mohindru Ph.D. Vice President - Corporate Strategy and Investor Relations
Bio & Compensation  - Reuters
Tania Chander Pharm.D. Vice President - Product Development
Bio & Compensation  - Reuters
Mark W. Noel Vice President - Technology Management and Intellectual Property
Age: 54
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Kenneth J. Pienta M.D. Director
Age: 53
Bio & Compensation  - Reuters
Martyn D. Greenacre Independent Director
Age: 72
Bio & Compensation  - Reuters